This #BloodCancerAwarenessMonth, join us in recognizing, supporting, and uplifting patients living with blood cancer – we see you, and you are not alone. Kura is deeply committed to advancing therapies to address the unmet need in #bloodcancer treatments, including NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (#AML). See our CMO Stephen Dale, M.D.’s thoughts on the progress and future of targeted therapies for blood cancers. Learn more about our investigational menin inhibitor for AML: https://lnkd.in/gsQRH6z3 #CancelBloodCancer #BCAM24
Kura Oncology, Inc.
Biotechnology Research
San Diego, California 20,659 followers
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
Über uns
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
- Website
-
http://www.kuraoncology.com
External link for Kura Oncology, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- San Diego, California
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2014
- Spezialitäten
- Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
Standorte
-
Primäre
12730 High Bluff Dr
Suite 400
San Diego, California 92130, US
-
2 Seaport Ln
Suite 8A
Boston, Massachusetts 02210, US
Employees at Kura Oncology, Inc.
Aktualisierungen
-
More than 1000 people are diagnosed with #leukemia every day; however, the nonspecific signs and symptoms make it difficult to recognize. On #WorldLeukemiaDay, join Kura Oncology and Acute Leukemia Advocates Network in raising awareness of the signs and symptoms of this condition. By helping more people get diagnosed earlier, we can help reduce the number of preventable deaths and improve outcomes. See the most common symptoms and #BeLeukemiaAware: https://bit.ly/3MuHAFi #WLD24 Learn more about Kura’s commitment to helping patients with acute leukemia lead better, longer lives: https://bit.ly/4dPuwGs
-
Visit us at SOHO 2024, Booth #154, and learn the latest on the KOMET clinical trial program and ziftomenib, an investigational menin inhibitor, in acute leukemias. KOMET-001 phase 2 registration-enabling study in R/R NPM1-m AML: Enrollment complete KOMET-007 and KOMET-008 phase 1 ziftomenib combination studies in newly diagnosed or R/R NPM1-m or KMT2A-r AML: Actively recruiting Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation by the FDA for R/R NPM1-m AML. Find out more about ziftomenib at #SOHO2024. More on the KOMET clinical trials is available here: https://bit.ly/3RUb9mS
-
-
With advancements in technology and an enhanced understanding of cancer biology, we can now both treat cancer once it’s developed, and identify ways to prevent new cancerous cells from forming. In a recent Empowered Patient Podcast episode with host Karen Jagoda, our Executive Vice President of Clinical Development, Mollie Leoni, MD explains how our menin inhibitor #ziftomenib targets key mutations that trigger the onset of #AML, promoting differentiation of cancerous cells into normal cells, and potentially halting the disease. Listen to the full podcast episode here: https://lnkd.in/gSNPnx8E
-
Menin inhibitors, including #ziftomenib, show potential to treat acute leukemias including NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (#AML). In a recent Nature article, Ken Garber breaks down the menin inhibitor space, including targets, data to date, and the potential menin inhibitors have to provide a new hope to patients. Read the full article here: https://bit.ly/3X8GfKE
-
The recent completion of the KOMET-001 trial enrollment is not only a major milestone for the many clinical investigators who work tirelessly for their patients, but is also an important step in advancing AML treatment. Early data indicate that this milestone brings us closer to realizing the potential of ziftomenib and better understanding NPM1-m AML. Discover the latest on KOMET-001 and actively recruiting KOMET trials in AML: https://bit.ly/3xL3bWd
-
Kura CEO Troy Wilson, Ph.D., J.D. joined fellow panelists at #FierceJPM Week to discuss the balancing of multiple factors— including market demand, legislation, patient interest and company resources— in efficiently advancing #drugdevelopment. Hear more in the clip below and view more highlights from the panel here: https://bit.ly/46HsLIK
-
Today we announced our Q2 2024 #earnings and shared updates on business and pipeline milestones as we look toward the rest of the year. View the full release: https://bit.ly/4fyKPZz Tune in to our investor webcast call today at 4:30 p.m. ET.
-
Our IND application for ziftomenib in advanced gastrointestinal stromal tumors (GIST) has been cleared by the FDA. This milestone represents the first IND clearance of a menin inhibitor to treat #GIST, a solid tumor indication with limited available treatment options for patients. Stay tuned as we present preclinical data supporting #ziftomenib’s potential to treat GIST in combination with imatinib at an upcoming scientific meeting and initiate a proof-of-concept clinical study early next year. Read the full announcement: https://lnkd.in/e8HapyA5
-
We’re grateful to our partners and friends at Life Science Cares San Diego and Mama's Kitchen for providing us an avenue to give back to our community. #ICYMI - in June, our partnership allowed us to provide support to critically ill patients struggling with food insecurity in San Diego. Hear more about our partnership efforts from our President and CEO Troy Wilson, Ph.D., J.D. as he recaps the event: https://bit.ly/3Szu46P
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 150.0M